Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
AssigneeBrigham Young University
InventorsPaul B. Savage, Michael C. Moore
Life of this patent
Estimating the term…
Abstract
The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition to a subject, and the deactivation composition deactivating coronavirus virions in the subject or coming into contact with the subject. The method can thereby prevent, decrease, or inhibit a coronavirus infection, such as COVID-19, of the subject.
Claims20
A method of treating a coronavirus infection in a subject, the method comprising:
- providing a deactivation composition including a cationic steroidal antimicrobial (CSA) compound in a carrier, wherein the CSA compound has a chemical structure of Formula IV, or salt thereof:
- where,
- R3, R7, and R12 are independently selected from the group consisting of aminoalkyloxy, aminoalkylcarboxy, aminoalkylurethanyl, aminoalkenyl-urethanyl, aminoalkynylurethanyl, and aminoarylurethanyl;
- and
- R18 is selected from the group consisting of alkylaminoalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkylcarbonylalkyl, di(alkyl)aminoalkyl, alkylcarboxyalkyl, hydroxyalkyl, terpenylcarboxyalkyl, terpenylcarbonyloxyalkyl, terpenylcarboxamido-alkyl, terpenylaminoalkyl, and terpenyloxyoalkyl;
- and
- administering the deactivation composition to the subject, wherein the deactivation composition treats the coronavirus infection in the subject by deactivating coronavirus virions in the subject or that come into contact with the subject.
A method of treating a coronavirus infection in a subject, the method comprising:
- providing a deactivation composition including one or more cationic steroidal antimicrobial (CSA) compounds in a carrier, the one or more CSA compounds having a chemical structure of Formula IV, or salt thereof:
- where,
- R3, R7, and R12 are independently selected from the group consisting of aminoalkyloxy and aminoalkylcarboxy;
- and
- R18 is selected from the group consisting of alkylaminoalkyl, di(alkyl)aminoalkyl, and alkylcarboxyalkyl;
- and
- administering the deactivation composition to the subject, wherein the deactivation composition treats the coronavirus infection in the subject by deactivating coronavirus virions in the subject or that come into contact with the subject.
A method of treating a coronavirus infection in a subject, the method comprising:
- providing a deactivation composition including one or more cationic steroidal antimicrobial (CSA) compounds in a carrier, wherein the one or more CSA compounds are selected from the group consisting of:
- CSA-13, CSA-43, CSA-44, CSA-45, CSA-90, CSA-131, CSA-136, CSA-137, CSA-138, CSA-141, CSA-142, CSA-144, CSA-145, CSA-146, and CSA-148;
- and
- administering the deactivation composition to the subject, wherein the deactivation composition treats the coronavirus infection in the subject by deactivating coronavirus virions in the subject or that come into contact with the subject.
Dependencies are inferred from the claim text.